Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase EARLY_PHASE1 1Phase 2 1

Status

Completed 2Active not recruiting 2Terminated 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 5

Conditions

Melanoma 47Carcinoma, Non-Small-Cell Lung 16Colorectal Neoplasms 14Lung Neoplasms 11Neoplasm Metastasis 10Pancreatic Neoplasms 9Brain Neoplasms 9Neoplasms 8Triple Negative Breast Neoplasms 6Skin Neoplasms 5Colonic Neoplasms 5Rectal Neoplasms 4Ovarian Neoplasms 4Uveal Melanoma 3Thyroid Neoplasms 3Multiple Myeloma 3Hematologic Neoplasms 3Glioma 3Gastrointestinal Stromal Tumors 3Breast Neoplasms 3Biliary Tract Neoplasms 3Solid Tumor 2Skin Diseases 2Recurrence 2Neurofibromatosis 1 2Lymphoma 2Leukemia, Hairy Cell 2Hereditary Sensory and Autonomic Neuropathies 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2

Interventions

pembrolizumab 24Nivolumab 23aldesleukin 21Cyclophosphamide 20Ipilimumab 17Interleukin-2 17fludarabine 15fludarabine phosphate 14cemiplimab 12Radiotherapy 7Fluorouracil 7Biopsy 7dabrafenib 6Surveys and Questionnaires 6Dacarbazine 6trametinib 5binimetinib 5Vemurafenib 5Temozolomide 5Surgical Procedures, Operative 5Sirolimus 5Radiation 5Blood Specimen Collection 5Aminolevulinic Acid 5sonidegib 4encorafenib 4Photochemotherapy 4Mohs Surgery 4HhAntag691 4Educational Status 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Skin Neoplasms × binimetinib × Clear all
NCT04657991 2026-04-07

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

Pfizer

Phase 3 Active not recruiting
257 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT05926960 2026-03-09

PORTSIDE

Pfizer

Phase 2 Terminated
38 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT01909453 2026-02-27

COLUMBUS

Pfizer

Phase 3 Completed
921 enrolled 48 charts 1 FDA
Dermatologic

Melanoma, Neoplasm Metastasis, Neoplasms, Skin Diseases, Skin Neoplasms

NCT03543969 2026-02-05

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Active not recruiting
14 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT01763164 2021-03-22

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

Pfizer

Phase 3 Completed
402 enrolled 21 charts
Dermatologic

Melanoma, Neoplasm Metastasis, Skin Diseases, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡